| (USD) | Dec 2022 | Q/Q |
|---|---|---|
| Revenue | 1B | +9% |
| Gross Profit | 579.7MM | +7% |
| Cost Of Revenue | 454MM | +11% |
| Operating Income | 280.2MM | +2% |
| Operating Expenses | 299.5MM | +13% |
| Net Income | 224.9MM | +7% |
| R&D | 69.9MM | +11% |
| G&A | 211.7MM | +9% |
| Amortization | 7.3MM | +15% |
| Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%Operating cash flows of $402 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2024. Third Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 7% to $1.2 billion; up
Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beyond analysts' top -and-bottom-line estimates for ResMed (RMD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.
Eli Lilly stock popped Wednesday after the company's weight-loss drug significantly reduced nighttime sleep apnea events.
A new study is boosting stock in drugmaker Eli Lilly—and knocking the shares of some medical-device makers. Eli Lilly’s drug Zepbound significantly reduced the severity of sleep apnea in patients in a new study, while also helping them lose weight. Obstructive sleep apnea is a disorder that blocks or restricts breathing during sleep, and obesity often contributes to it.
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:http://investor.resmed.com • Da